UNSPSC 51332305: Pimozide

This classification denotes an antipsychotic agent with the molecular formula C28H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HIZ4DL86F, chemically known as 2h-benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- but generally known as pimozide, which bears US NIH Compound Identifier 16362. European Medicines Agency schedules Pimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09847MIG.

UNSPSC 51332305 Pimozide is a Commodity code that nominally designates a single antipsychotic pharmaceutical product, but recent state and local procurement activity under this code shows a significant mismatch: Seminole County, Florida posted an IFB for Naloxone and Safe Drug Deactivation Systems — opioid-overdose reversal medication and drug-disposal equipment — neither of which falls within the scope of pimozide or antipsychotic pharmaceuticals. The county's solicitation reflects community health and public safety priorities around overdose response and controlled-substance management rather than psychiatric medication procurement. This code shows limited recent activity, and the single posted opportunity appears to be a tagging anomaly rather than authentic commodity-level demand for pimozide in state and local government.

Seminole County's IFB (IFB60459723LAS), posted June 30, 2026 with a response deadline of July 26, 2023, calls for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option, fixed-fee pricing structure, and potential FEMA funding with accompanying federal compliance requirements including Clean Air Act and Federal Water Pollution Control Act adherence. Vendors must comply with drug-free workplace certification, E-Verify employment eligibility verification, and specified insurance coverage including workers' compensation and commercial general liability. No set-aside designations or disadvantaged-enterprise restrictions are noted. The mismatch between the code's pharmaceutical designation and the solicited products suggests this code warrants careful verification before pursuit; state and local procurement systems occasionally tag opportunities with incorrect UNSPSC codes, and this appears to be one such instance.